Use the labels in the right column to find what you want. Or you can go thru them one by one, there are only 29,985 posts. Searching is done in the search box in upper left corner. I blog on anything to do with stroke. DO NOT DO ANYTHING SUGGESTED HERE AS I AM NOT MEDICALLY TRAINED, YOUR DOCTOR IS, LISTEN TO THEM. BUT I BET THEY DON'T KNOW HOW TO GET YOU 100% RECOVERED. I DON'T EITHER BUT HAVE PLENTY OF QUESTIONS FOR YOUR DOCTOR TO ANSWER.
Changing stroke rehab and research worldwide now.Time is Brain!trillions and trillions of neuronsthatDIEeach day because there areNOeffective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.
What this blog is for:
My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.
Saturday, March 6, 2021
Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection
Finally some doctors putting together treatment prior to hospital. Although maybe HCQ is no longer considered, so ask your doctor.
Approximately
9 months of the severe acute respiratory syndrome coronavius-2
(SARS-CoV-2 [COVID-19]) spreading across the globe has led to widespread
COVID-19 acute hospitalizations and death. The rapidity and highly
communicable nature of the SARS-CoV-2 outbreak has hampered the design
and execution of definitive randomized, controlled trials of therapy
outside of the clinic or hospital. In the absence of clinical trial
results, physicians must use what has been learned about the
pathophysiology of SARS-CoV-2 infection in determining early outpatient
treatment of the illness with the aim of preventing hospitalization or
death. This article outlines key pathophysiological principles that
relate to the patient with early infection treated at home. Therapeutic
approaches based on these principles include 1) reduction of
reinoculation, 2) combination antiviral therapy, 3) immunomodulation, 4)
antiplatelet/antithrombotic therapy, and 5) administration of oxygen,
monitoring, and telemedicine. Future randomized trials testing the
principles and agents discussed will undoubtedly refine and clarify
their individual roles; however, we emphasize the immediate need for
management guidance in the setting of widespread hospital resource
consumption, morbidity, and mortality.
COVID-19 hospitalizations and death can be reduced with outpatient treatment.
•
Principles
of COVID-19 outpatient care include: 1) reduction of reinoculation, 2)
combination antiviral therapy, 3) immunomodulation, 4)
antiplatelet/antithrombotic therapy 5) administration of oxygen,
monitoring, and telemedicine.
•
Future
randomized trials will undoubtedly refine and clarify ambulatory
treatment, however we emphasize the immediate need for management
guidance in the current crisis of widespread hospital resource
consumption, morbidity, and mortality.
The
pandemic of severe acute respiratory syndrome coronavius-2 (SARS-CoV-2
[COVID-19]) is rapidly expanding across the world with each country and
region developing distinct epidemiologic patterns in terms of frequency,
hospitalization, and death. There has been considerable focus on 2
major areas of response to the pandemic: containment of the spread of
infection and reducing inpatient mortality. These efforts, although
well-justified, have not addressed the ambulatory patient with COVID-19
who is at risk for hospitalization and death. The current epidemiology
of rising COVID-19 hospitalizations serves as a strong impetus for an
attempt at treatment in the days or weeks before a hospitalization
occurs.1
Most patients who arrive to the hospital by emergency medical services
with COVID-19 do not initially require forms of advanced medical care.2
Once hospitalized, approximately 25% require mechanical ventilation,
advanced circulatory support, or renal replacement therapy. Hence, it is
conceivable that some, if not a majority, of hospitalizations could be
avoided with a treat-at-home first approach with appropriate
telemedicine monitoring and access to oxygen and therapeutics.3 As
in all areas of medicine, the large randomized, placebo-controlled,
parallel group clinical trial in appropriate patients at risk with
meaningful outcomes is the theoretical gold standard for recommending
therapy. These standards are not sufficiently rapid or responsive to the
COVID-19 pandemic.4 One could argue the results of definitive trials were needed at the
outset of the pandemic, and certainly are needed now with more than 1
million cases and 500,000 deaths worldwide.5
Because COVID-19 is highly communicable, many ambulatory clinics do not
care for patients in face-to-face visits, and these patients are
commonly declined by pharmacies, laboratories, and imaging centers. On
May 14, 2020, after about 1 million cases and 90,000 deaths in the
United States had already occurred, the National Institutes of Health
(NIH) announced it was launching an outpatient trial of
hydroxychloroquine (HCQ) and azithromycin in the treatment of COVID-19.6
A month later, the agency announced it was closing the trial because of
the lack of enrollment with only 20 of 2000 patients recruited.7 No safety concerns were associated with the trial. This effort serves
as the best current working example of the lack of feasibility of
outpatient trials for COVID-19. It is also a strong signal that future
ambulatory trial results are not imminent or likely to report soon
enough to have a significant public health impact on clinical outcomes.8 If
clinical trials are not feasible or will not deliver timely guidance to
clinicians or patients, then other scientific information bearing on
medication efficacy and safety needs to be examined. Cited in this
article are more than a dozen studies of various designs that have
examined a range of existing medications. Thus, in the context of
present knowledge, given the severity of the outcomes and the relative
availability, cost, and toxicity of the therapy, each physician and
patient must make a choice: watchful waiting in self-quarantine or
empiric treatment with the aim of reducing hospitalization and death.
Because COVID-19 expresses a wide spectrum of illness progressing from
asymptomatic to symptomatic infection to fulminant adult respiratory
distress syndrome and multiorgan system failure, there is a need to
individualize therapy according to what has been learned about the
pathophysiology of human SARS-CoV-2 infection.9 It is beyond the scope of this article to review every preclinical and
retrospective study of proposed COVID-19 therapy. Hence, the agents
proposed are those that have appreciable clinical support and are
feasible for administration in the ambulatory setting. SARS-CoV-2 as
with many infections may be amenable to therapy early in its course but
is probably not responsive to the same treatments very late in the
hospitalized and terminal stages of illness.10For
the ambulatory patient with recognized early signs and symptoms of
COVID-19, often with nasal real-time reverse transcription or oral
antigen testing pending, the following 4 principles could be deployed in
a layered and escalating manner depending on clinical manifestations of
COVID-19-like illness11
and confirmed infection: 1) reduction of reinoculation, 2) combination
antiviral therapy, 3) immunomodulation, and 4)
antiplatelet/antithrombotic therapy. Because the results of testing
could take up to a week to return, treatment can be started before the
results are known. For patients with cardinal features of the syndrome
(ie, fever, body aches, nasal congestion, loss of taste and smell, etc.)
and suspected false-negative testing, treatment can be the same as
those with confirmed COVID-19.11
Future randomized trials are expected to confirm, reject, refine, and
expand these principles. In this article, they are set forth in
emergency response to the growing pandemic as shown in Figure 1.
Figure 1Treatment
algorithm for COVID-19-like and confirmed COVID-19 illness in
ambulatory patients at home in self-quarantine. BMI = body mass index;
CKD = chronic kidney disease; CVD = cardiovascular disease;
DM = diabetes mellitus; Dz = disease; HCQ = hydroxychloroquine;
Mgt = management; O2 = oxygen; Ox = oximetry; Yr = year.
No comments:
Post a Comment